BMO cuts Zimmer Biomet stock price target on debt refinancing costs

BMO Capital reduced its price target for Zimmer Biomet (ZBH) to $101 from $102, citing higher debt refinancing costs. The company issued €500M and $500M in notes, adding ~$17M in annual interest expense. ZBH's Q3 2026 revenue was $2.06B, beating estimates, with EPS flat at $1.90. Analysts adjusted targets, with Stifel at $140 and Jefferies at $120.

Original reporting
Published Nov 16, 2026, 2:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 2:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ZBH
Bearish
medium confidence
Mentioned
$ZBH
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ZBHBearishMed
01

Why it matters

BMO’s target reduction is driven by estimated incremental annual interest expense (~$17M) and a small reduction in 2027 EPS estimate ($8.78 vs $8.85), implying a near-term earnings headwind from refinancing costs.

02

Market read

Traders may adjust expectations for ZBH’s earnings trajectory and valuation sensitivity to refinancing costs following the analyst’s updated model inputs.

03

What to watch

The offering materials do not specify use of proceeds; if proceeds refinance maturities efficiently or extend duration, the long-run balance-sheet impact could be less negative than the incremental interest expense implies.

Relevance 6/10Novelty 6/10Timing: analyst target change reported today, tied to the Nov 12 debt offering

Background

Zimmer Biomet announced a dual-currency debt offering on Nov 12, issuing €500M 4.375% notes due 2033 and $500M 5.850% notes due 2036.

Company-level read

Ticker impact

$ZBHBearishMedium confidence
Context

BMO cut Zimmer Biomet’s price target to $101 after the company announced a dual-currency debt offering that raises annual interest expense.

Expected impact

Likely modest downside bias as the market prices higher interest expense and the reduced 2027 EPS outlook.

Evidence & confidence

The article ties the target cut directly to incremental annual interest expense (~$17M) and a reduced 2027 EPS estimate, both of which affect near-term earnings power and valuation.

Market effects

Medical device peers with similar leverage/refinancing profiles may see read-across on interest-rate sensitivity and valuation multiples.

Limited, primarily affects US large-cap medical device sentiment rather than broad regional risk.

Euro and USD note issuance highlights cross-currency funding conditions, but the impact is company-specific.

Counterpoint

The article notes InvestingPro still flags ZBH as undervalued versus fair value, suggesting the target cut may be more about near-term EPS optics than long-term fundamentals.

Key entities

  • Zimmer Biomet Holdings Inc.

    Subject of the analyst price-target cut tied to debt refinancing costs and updated EPS estimates.

  • BMO Capital

    Lowered ZBH price target to $101 from $102 while maintaining Market Perform.

Related articles

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

$ZBHMed

Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

$ZBHMed

Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.